The phase 1 trial NCT01295827 will test several doses of the antibody in patients with NSCLC and other cancers, and will also examine expression of PD-L1 in tumors, based on the results cited above that showed a strong correlation of the efficacy of Nivolumab with PD-L1 expression. Here, CD274 is linked to cancer.